IDYA
Price
$32.07
Change
+$0.12 (+0.38%)
Updated
Nov 13, 03:45 PM (EDT)
Capitalization
2.8B
138 days until earnings call
Intraday BUY SELL Signals
NUVL
Price
$94.19
Change
-$2.84 (-2.93%)
Updated
Nov 13, 03:56 PM (EDT)
Capitalization
7.06B
111 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IDYA vs NUVL

Header iconIDYA vs NUVL Comparison
Open Charts IDYA vs NUVLBanner chart's image
IDEAYA Biosciences
Price$32.07
Change+$0.12 (+0.38%)
Volume$150
Capitalization2.8B
Nuvalent
Price$94.19
Change-$2.84 (-2.93%)
Volume$100
Capitalization7.06B
IDYA vs NUVL Comparison Chart in %
IDYA
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
IDYA vs. NUVL commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a StrongBuy and NUVL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (IDYA: $31.95 vs. NUVL: $97.03)
Brand notoriety: IDYA and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 69% vs. NUVL: 61%
Market capitalization -- IDYA: $2.8B vs. NUVL: $7.06B
IDYA [@Biotechnology] is valued at $2.8B. NUVL’s [@Biotechnology] market capitalization is $7.06B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 1 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • IDYA’s FA Score: 1 green, 4 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, IDYA is a better buy in the long-term than NUVL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 3 TA indicator(s) are bullish while NUVL’s TA Score has 3 bullish TA indicator(s).

  • IDYA’s TA Score: 3 bullish, 5 bearish.
  • NUVL’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both IDYA and NUVL are a bad buy in the short-term.

Price Growth

IDYA (@Biotechnology) experienced а +7.72% price change this week, while NUVL (@Biotechnology) price change was +5.36% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

IDYA is expected to report earnings on Mar 31, 2026.

NUVL is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($7.06B) has a higher market cap than IDYA($2.8B). IDYA (24.319) and NUVL (23.952) have similar YTD gains . NUVL (-362.01M) and IDYA (-380.2M) have comparable annual earnings (EBITDA) . NUVL has more cash in the bank: 1.01B vs. IDYA (670M). IDYA has higher revenues than NUVL: IDYA (7M) vs NUVL (0).
IDYANUVLIDYA / NUVL
Capitalization2.8B7.06B40%
EBITDA-380.2M-362.01M105%
Gain YTD24.31923.952102%
P/E RatioN/AN/A-
Revenue7M0-
Total Cash670M1.01B67%
Total Debt26.6MN/A-
FUNDAMENTALS RATINGS
IDYA: Fundamental Ratings
IDYA
OUTLOOK RATING
1..100
79
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
PROFIT vs RISK RATING
1..100
63
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
38
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
IDYANUVL
RSI
ODDS (%)
Bearish Trend 2 days ago
67%
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 2 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
77%
Bearish Trend 4 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SGIFX41.480.30
+0.73%
Steward Global Equity Income Fund C
FEEFX96.370.23
+0.24%
American Funds Fundamental Invs 529-F-3
WFALX22.630.02
+0.09%
Allspring Index Asset Allocation C
SPECX36.89-0.34
-0.91%
Alger Spectra A
RPFRX39.83-0.39
-0.97%
Davis Real Estate A

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with NUVL. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
-0.19%
NUVL - IDYA
59%
Loosely correlated
+0.91%
NRIX - IDYA
58%
Loosely correlated
-5.37%
IMNM - IDYA
57%
Loosely correlated
-0.51%
CGON - IDYA
57%
Loosely correlated
+1.47%
XENE - IDYA
57%
Loosely correlated
-0.60%
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with RVMD. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
+0.91%
RVMD - NUVL
62%
Loosely correlated
+2.73%
XENE - NUVL
61%
Loosely correlated
-0.60%
XNCR - NUVL
60%
Loosely correlated
-3.23%
IDYA - NUVL
59%
Loosely correlated
-0.19%
CGON - NUVL
58%
Loosely correlated
+1.47%
More